|
Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico |
Salinas-Escudero G, Martinez-Valverde S, Reyes-Lopez A, Garduno-Espinosa J, Munoz-Hernandez O, Granados-Garcia V, Rely K |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Salinas-Escudero G, Martinez-Valverde S, Reyes-Lopez A, Garduno-Espinosa J, Munoz-Hernandez O, Granados-Garcia V, Rely K. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico. Salud Publica de Mexico 2012; 54(1): 47-59 Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal, Humanized /economics /therapeutic use; Antiviral Agents /economics /therapeutic use; Cost-Benefit Analysis; Decision Trees; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases /prevention & Mexico; Palivizumab; Respiratory Syncytial Virus Infections /economics /prevention & control; control AccessionNumber 22012025825 Date bibliographic record published 23/01/2013 |
|
|
|